ID 112344
Title Alternative
Tumor size and proliferative marker geminin levels associated with SUVmax levels on PET for breast cancers
Author
Nishimukai, Arisa Hyogo College of Medicine
Inoue, Natsuko Hyogo College of Medicine
Kira, Ayako Hyogo College of Medicine
Takeda, Masashi Yao Municipal Hospital
Morimoto, Koji Osaka Women's Junior College|Osaka National Hospital
Araki, Kazuhiro Hyogo College of Medicine
Kitajima, Kazuhiro Hyogo College of Medicine
Watanabe, Takahiro Hyogo College of Medicine
Hirota, Seiichi Hyogo College of Medicine
Nakamori, Shoji Osaka National Hospital
Akazawa, Kouhei Niigata University
Miyoshi, Yasuo Hyogo College of Medicine
Content Type
Journal Article
Description
It has been well established that maximum standardized uptake value (SUVmax) for 18F-fluorodeoxyglucose positron-emission tomography/computed tomography (FDG PET/CT) is clinically useful for evaluating treatment efficacy as well as predicting prognosis of breast cancer patients. Although SUVmax reflects increased glucose uptake and metabolism possibly induced by activation of growth factor signaling or TP53 dysfunction, tumor characteristics of SUVmax-high breast cancers remain to be elucidated. For the present study, we used immunohistochemical staining to investigate expressions of phospho-ribosomal protein S6 (pS6, downstream molecule of phosphatidyl inositol 3-kinase/Akt/mammalian target of the rapamycin/S6K pathway) and phosphor-p44/42 mitogen-activated protein kinase (pMAPK). Expression levels of TP53 and proliferative marker geminin as well as Ki67 were also examined by means of immunostaining in 163 invasive breast cancers. Cutoff values were set at 10% for pS6, 20% for pMAPK and TP53, and 4% for geminin. The SUVmax levels were significantly higher in the pS6-positive (p = 0.0173), TP53-positive (p = 0.0207) and geminin-high cancers (p<0.0001), but there was no significant association between pMAPK expression levels and SUVmax levels. Multivariable analysis showed that a high geminin level (odds ratio: 6.497, 95% confidence interval: 2.427-19.202, p = 0.0001) and large tumor size (6.438, 2.224-20.946, p = 0.0005) were significantly and independently associated with SUVmax-high. Univariable but not multivariable analysis indicated that Ki67-high significantly correlated with SUVmax-high. Twenty of 23 (87.0%) breast cancers with tumor size >2cm and geminin-high showed SUVmax-high, while only 6 of 49 (12.2%) breast cancers ≤2cm in size and with low geminin levels were SUVmax-high. In conclusion, we could determine that breast cancers with a large tumor and a geminin-high rather than Ki67- high proliferative marker were significantly associated with high levels of SUVmax. These findings may signify that SUVmax reflects tumor characteristics with high proliferative activity but not activation of mTOR/S6K and MAPK pathways or increased glucose metabolism due to dysfunction of TP53.
Journal Title
PLOS ONE
ISSN
19326203
Publisher
PLOS
Volume
12
Issue
9
Start Page
e0184508
Published Date
2017-09-08
Rights
Copyright: © 2017 Nishimukai et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
EDB ID
DOI (Published Version)
URL ( Publisher's Version )
FullText File
language
eng
TextVersion
Publisher
departments
Institute of Advanced Medical Sciences